ProCE Banner Activity

Brentuximab Vedotin + ESHAP in R/R Classical Hodgkin’s Lymphoma

Slideset Download
Conference Coverage
Phase I/II data suggest promise of combining brentuximab vedotin with ESHAP for patients with relapsed/refractory cHL who are transplantation candidates.

Released: December 15, 2015

Expiration: December 13, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen